Iatrogenic Cushing’s syndrome with inhaled steroid plus antidepressant drugs by Ozlem Celik et al.
Celik et al. Multidisciplinary Respiratory Medicine 2012, 7:26
http://www.mrmjournal.com/content/7/1/26CASE REPORT Open AccessIatrogenic Cushing’s syndrome with inhaled
steroid plus antidepressant drugs
Ozlem Celik, Mutlu Niyazoglu, Hikmet Soylu and Pinar Kadioglu*Abstract
Current guidelines recommend the use of inhaled corticosteroids (ICS) for suppression of airway inflammation in
patients with asthma. Although it is well known that ICS cause dose-related adrenocortical suppression, it is less
known that they can lead to iatrogenic Cushing’s syndrome (CS). Fluticasone propionate (FP) is an ICS more potent
than beclomethasone and budesonide. FP is metabolized as mediated by cytochrome P450 3A4 in the liver and
the gut. Systemic bioactivity of FP can increase with the use of drugs that affect the cytochrome P450. Herein, we
report the rapid development of iatrogenic CS in a patient receiving paroxetine and mirtazepine for 12 weeks in
addition to inhaled FP.
Keywords: Cushing’s syndrome, Fluticasone propionate, Mirtazepine, ParoxetineBackground
Inhaled corticosteroids (ICS) are widely accepted as the first
line of treatment for the suppression of airway inflamma-
tion of asthma [1,2]. Although it is well known that ICS
cause dose-related adrenocortical suppression, it is less
known that they can lead to iatrogenic Cushing’s syndrome
(CS) [3-5]. Fluticasone propionate (FP) is the most potent
inhaled corticosteroid and is highly lipophilic with a large
volume of distribution. Low plasma concentrations of FP
are achieved after inhaled dosing due to first-pass metabol-
ism and high systemic clearance, mediated by cytochrome
P450 3A4 in the liver and the gut [6]. Systemic bioactivity
of FP depends on: glucocorticoid potency, dose, duration of
therapy, individual glucocoticoid receptor sensitivity, and
drug combinations. Previously, iatrogenic CS was recog-
nized after prolonged high dose use of FP in a female patient
[3]. The literature presents many reports of iatrogenic CS
with osteoporosis and secondary adrenal failure in Human
Immunodeficiency Virus (HIV)-infected patients receiving
ICS and ritonavir [7].
Paroxetine and mirtazepine are antidepressant drugs
that inhibit cytochrome P450 and, consequently, decrease
the clearance of corticosteroids. Paroxetine is highly meta-
bolized with cytochrome P450- dependent CYP2D6. There
is a moderate effect on other P450 enzymes. Although* Correspondence: kadioglup@yahoo.com
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reproduction in any medium, provided the ormirtazepine is a weak competitive inhibitor of CYP 1A2,
2D6 and 3A4, it is known that there have been no clinical
effects on cytochrome P450 to date [8].
Herein, we report for the first time the rapid develop-
ment of iatrogenic CS in a patient who has been taking
paroxetine and mirtazepine, in addition to inhaled FP,
for 12 weeks.Case presentation
A 30-year-old female patient who had weakness, hirsutism,
acne, increased abdominal fat and purple strias was admit-
ted to the Endocrinology and Metabolism out-patient clinic
of Cerrahpasa Medical School, University of Istanbul. She
had been diagnosed with depression and asthma three
months earlier. The patient had been receiving inhaled FP
(500 mcg twice daily) and paroxetine (20mg/day, po.), mirta-
zepine (30 mg/day, po.) therapies with no evidence of CS
(Figure 1). The patient complained of central weight gain,
muscle wasting, weakness, easy bruising, hirsutism, acne
and abdominal striae after treatment with FP for three
months. Obvious moon face (Figure 2a), facial plethora,
acne, oral mucositis, increased truncal and abdominal fat,
buffalo hump, proximal myopathy and hirsutism were noted
at the physical examination. Prominent striae were evident
on her abdomen and arms (Figure 2b). Blood pressure was
135/80 mmHg with no postural drop. Sub-acute throm-
bosis, caused by edema and swelling in the right leg, was
detected by Doppler USG in the patient’s right popliteald. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Patient’s facial appearance before starting inhaled
fluticasone propionate and antidepressants.
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http://www.mrmjournal.com/content/7/1/26vein. Enoxaparin sodium 0.6 ml twice daily was started. The
patient was not osteoporotic.
An early morning cortisol of 0.8 μg/dl, ACTH of 1 pg/ml
and a urinary free cortisol excretion of 60 mg/day were
determined. Initial laboratory results are shown in Table 1.
A short synacthen test (1 μg) was clearly abnormal, rising
to 3μg/dl and 3.4 μg/dl at 30 and 60 minutes, respectively.
After consultation with a thoracic diseases specialist,
the patient was reassessed for asthma. Respiratory func-
tion tests were as follows: FEV1: 2.67, FEV1/FVC: 97,a
Figure 2 a - Patient’s facial appearance 3 months after therapy with i
and strias were shown in the patient with iatrogenic Cushing’s syndrPEF: 6.16, MEF25-75: 4.51. FP was changed to salbutamol
sulphate as needed for a re-evaluation of the diagnosis.
The patient developed symptoms of extreme fatigue, anor-
exia, and myalgia after cessation of FP. Hydrocortisone (20
mg /day for 2 months, po), at gradually decreasing doses, was
started for evaluation of the hypothalamic-pituitary-adrenal
axis. Two months after withdrawal of FP, the patient felt that
her clinical appearance was better, but there was still evidence
of hypothalamic-pituitary-adrenal (HPA) axis suppression.
Discussion
A case of clinical CS secondary to increased systemic con-
centration of FP due to cytochrome P450 inhibition has
been described. The condition of the patient was associated
with subsequent adrenal insufficiency related to the sup-
pression of pituitary-adrenal axis.
FP undergoes very high first-pass hepatic metabolism,
mediated by cytochrome P450 3A4, and it is also very lipo-
philic, resulting in much higher tissue levels, longer plasma
half-life and greater glucocorticoid receptor affinity than
other ICSs such as beclomethasone and budenoside [9]. Re-
cently, HPA axis suppression related to ICS is thought to be
due to systemic absorption through the lungs rather than
oral absorption via ingested corticosteroids after inhalation
[10]. A recent retrospective study [11] aimed at estimating
the incidence of adrenal insufficiency in users of inhaled
corticosteroids reported 46 cases (involving fluticasone,
budesonide, or beclomethasone). Eleven patients treated
with fluticasone and four with budesonide were concomi-
tantly treated with an enzymatic inhibitor: itraconazole (six
cases), ritonavir (five cases), verapamil (two cases), and dil-
tiazem (two cases). Although the use of ICS in the long-
term management of asthma is recommended, it is advised
that the lowest effective dose of ICS be used to prevent sys-
temic side effects [1,12].b
nhaled fluticasone propionate and antidepressants. b - Hirsutism
ome.
Table 1 The initial laboratory results in patient with Iatrogenic Cushing’s syndrome
Results (normal range) Results (normal range)
ACTH : 1 pg/mL (0–46) Albumin : 3.7 gr/dL (3.2-4.8)
Cortisol : 0.8 μg/dL (5–25) AST : 41U/L (0–45)
Urinary free cortisol : 60 μg /day (20–70) ALT : 21U/L(10–45)
DHEAS : 9 μg/dL (35–430) Alkaline phosphatase : 42U/L (45–129)
Total testosterone : 15ng/dL (20–90) Calcium : 9 mg/dL (8.6-10)
Free T4 : 2.34ng/dl (0.8-1.58) Phosphorus : 2.9mg/dL (2.1-4)
TSH : 1.44mIU/L (0.4-4) Total cholesterol : 232mg/dL (50–200)
Glucose : 104mg/dL (74–106) Triglyceride : 68mg/dL(20–170)
Urea : 21mg/dL (19–50) HDL cholesterol : 79mg/dL(45–65)
Creatinine : 0.6mg/dL (0.7-1.3) LDL cholesterol : 139 mg/dL(5–130)
Sodium : 143mEq/L (135–145) CRP : < 3mg/L (0–5)
Potassium : 3.2 mEq/L (3.5-5.5) ESR : 9 mm/sa (5–25)
Leukocyte : 7700/mm3 (4600–10.000) Hemoglobin : 13 gr/dL(12–17)
Hematocrit : 38% (37–50) Platelet : 133000/mm3(150–450)
FEV1 : 2.67 L (2.83) FEV1/ FVC : 97% (83)
PEF : 6.16L/sec (6.59) MEF25-75 : 4.51L/sec (3.83)
Cortisol after 1 μg ACTH stimulation test (30th and 60th): 3 and 3.4 μg/dl (> 18 μg/dl).
Definition of abbreviations: ALT, serum alanine amino-transferase; AST serum amino-transferase; CRP, C reactive protein; DHEAS, dehydroepiandrosterone sulfate;
ESR, erythrocyte sedimentation rate; FEV, forced expiratory volume; FVC, forced vital capacity; MEF 25–75, mean forced expiratory flow between 25% and 75% of
FVC; PEF, peak expiratory flow.
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on adrenal function when prescribed within the therapeutic
range of 50–500 μg/day to patients with asthma [13]. It was
demonstrated that age, being a normal volunteer inhaler tech-
nique and compliance, plays a role in determining the sys-
temic effects of ICS. In spite of this, Paton J et al. reported
that clinical adrenal insufficiency was particularly associated
with high doses (> 400 μg/day) of inhaled FP in children with
asthma [4]. Wilson AM et al. demonstrated that high doses of
inhaled FP alone were associated with adrenal suppression
and CS features with use over 2 years in a female asthmatic
patient. Inhaled FP was changed to budenoside, then her
cushingoid features improved and HPA also returned to nor-
mal [3]. Recently Matos AC et al. presented a 22- year-oldTable 2 Some important drugs that inhibit cytochrome P450
CYP2D6
Antiarrhythmics (Flecainide, Propafenone, etc.)
Beta blockers (Carvedilol, Metoprolol, etc..)
Neuroleptics (Haloperidol, Risperidone, Clozapine, etc.)
Opiates (Dextromethorphan, Codeine, Tramadol, etc.)
SSRI (Fluoxetine, Paroxetine, Fluvoxamine, etc.)
Tricyclic antidepressants (Amitriptyline, Desipramine, Imipramine, Nortriptylineman with adrenal insufficiency and a cushingoid habitus who
was receiving 250 μg FP and salmeterol 50 μg two blisters,
twice a day for four years [10]. These cases confirms that HPA
axis suppression with features of Cushing’s syndrome occurs
at commonly used, and licensed, doses of ICS.
There is more evidence in the literature of iatrogenic CS
associated with the co-administration of inhaled FP with both
high doses and low doses of ritonavir used in the treatment of
HIV infection. Samaras K et al. reported six patients with
iatrogenic CS who had HIV infection and were receiving rito-
navir and FP combination. These patients demonstrated sig-
nificant disturbance of mood, osteoporosis and adrenal
insufficiency requiring supportive treatment after FP with-
drawal [7]. Clinical CS was shown in a patient with asthmadependent CYP3A4 and CYP2D6
CYP3A4
Antiarrhythmics (Amiodarone, Lidocaine, Propafenone, etc.)
Anti-histamines (Astemizole, Chlorpheniramine)
Anti-cancer (Tamoxifen, Vinblastine)
Benzodiazepines (Midozalam, Diazepam, Alprazolam, etc.)
HIV-protease inh (Ritonavir, Indinavir, etc.)
, etc.) HMG CoA reductaseinh (Atorvastatin, Lovastatine, Simvastatin)
Hormones (Cortisol, Progesterone, Testosterone, steroids)
Calcium channel blocker (Diltiazem, Verapamil, Nitrendipin)
Macrolides (Erythromycin, Clarithromycin)
Others (Ketoconazole, Itraconazole, Lidocaine, Cocaine,. . .etc)
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in FP clearance by inhibition of cytochrome P450 3A4 [14].
Hoover WC et al. reported a 9- year-old girl with cystic fi-
brosis (CF)-related liver disease and asthma. Seven weeks
after the initiation of inhaled fluticasone, she developed vagi-
nal candidiasis and was prescribed fluconazole 100 mg/day.
Iatrogenic Cushing syndrome was shown in this patient with
inhaled FP and a CYP3A4 inhibitor, fluconazole [15]. Table 2
shows that several drugs inhibit cytochrome P450 dependent
CYP3A4 and CYP2D6 and consequently decrease the clear-
ance of synthetic glucocorticoids. Importantly, adrenal sup-
pression does not occur in every patient treated with a
combination of these drugs and ICS. Variation in CYP3A4 ac-
tivity, in glucocorticoid receptor sensitivity, or in glucocorticoid
receptor polymorphism, in addition to patient age, may influ-
ence the response of the individual. There are reported cases
of children and adults with cushingoid features and adrenal
suppression due to budesonide with CYP3A4 inhibitors [16].
Paroxetine and mirtazepine are antidepressant drugs that
inhibit cytochrome P450, and, consequently, decrease the
clearance of corticosteroids. Although it is known that
paroxetine is highly metabolized with cytochrome P450-
dependent CYP2D6, mirtazepine has not known to have
clinical effects on cytochrome P450 to date [8]. However, it
should be verified with research and observations. It was
thought that our patient had developed clinical CS secondary
to increased systemic concentration of FP due to cytochrome
P450 inhibition by antidepressants. In addition to the CS de-
velopment, biochemical results of the patient showed low
cortisol, ACTH, testosterone, DHEAS (Dehydroepiandros-
terone sulfate) levels, and hypokalemia. Moreover, she had
impaired fasting glucose. Recently, declines in DHEAS after
the initiation of ICS have been recommended as an early
index of adrenal suppression [17]. Significantly low DHEAS
levels (9 μg/dl) were found in this patient. These findings
may provide significant clinical utility for the early detection
of adrenal suppression after ICS therapy.Conclusions
In conclusion, to the best of our knowledge, this is the first
report of a patient with iatrogenic CS receiving FP and anti-
depressants. Both thoracic diseases specialists and general
practitioners should be aware of the risk of iatrogenic CS
due to serious drug interactions with FP.Consent
Written informed consent was obtained from the patient
for publication of this case report and any accompanying
images. A copy of the written consent is available for review
by the Editor-in-Chief of this journal.
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